Abstract

In the gut ecosystem, microorganisms regulate group behaviour and interplay with the host via a molecular system called quorum sensing (QS). The QS molecule 3-oxo-C12:2-HSL, first identified in human gut microbiota, exerts anti-inflammatory effects and could play a role in inflammatory bowel diseases where dysbiosis has been described. Our aim was to identify which signalling pathways are involved in this effect. We observed that 3-oxo-C12:2-HSL decreases expression of pro-inflammatory cytokines such as Interleukine-1β (− 35%) and Tumor Necrosis Factor-α (TNFα) (− 40%) by stimulated immune RAW264.7 cells and decreased TNF secretion by stimulated PBMC in a dose-dependent manner, between 25 to 100 µM. Transcriptomic analysis of RAW264.7 cells exposed to 3-oxo-C12:2-HSL, in a pro-inflammatory context, highlighted JAK-STAT, NF-κB and TFN signalling pathways and we confirmed that 3-oxo-C12:2-HSL inhibited JAK1 and STAT1 phosphorylation. We also showed through a screening assay that 3-oxo-C12:2-HSL interacted with several human bitter taste receptors. Its anti-inflammatory effect involved TAS2R38 as shown by pharmacologic inhibition and led to an increase in intracellular calcium levels. We thus unravelled the involvement of several cellular pathways in the anti-inflammatory effects exerted by the QS molecule 3-oxo-C12:2-HSL.

Details

Title
3-oxo-C12:2-HSL, quorum sensing molecule from human intestinal microbiota, inhibits pro-inflammatory pathways in immune cells via bitter taste receptors
Author
Coquant, Garance 1 ; Aguanno, Doriane 2 ; Brot, Loïc 1 ; Belloir, Christine 3 ; Delugeard, Julie 1 ; Roger, Nathalie 1 ; Pham, Hang-Phuong 4 ; Briand, Loïc 3 ; Moreau, Marielle 5 ; de Sordi, Luisa 1 ; Carrière, Véronique 1 ; Grill, Jean-Pierre 1 ; Thenet, Sophie 2 ; Seksik, Philippe 6 

 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109) 
 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); PSL University, EPHE, Paris, France (GRID:grid.440907.e) (ISNI:0000 0004 1784 3645) 
 University of Bourgogne Franche-Comté, Centre des Sciences du Goût et de l’Alimentation, UMR 1324 INRAE, UMR 6265 CNRS, Dijon, France (GRID:grid.493090.7) (ISNI:0000 0004 4910 6615) 
 Parean Biotechnologies, Saint Malo, France (GRID:grid.50550.35) 
 LVMH Recherche, Life Science Department, Saint Jean de Braye, France (GRID:grid.480251.a) (ISNI:0000 0001 0276 1637) 
 Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France (GRID:grid.465261.2) (ISNI:0000 0004 1793 5929); Paris Center for Microbiome Medicine (PaCeMM) FHU, APHP, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); Sorbonne Université, Département de Gastroentérologie et Nutrition, APHP, Hôpital Saint-Antoine, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2674138222
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.